Man Group’s CorMedix CRMD Stock Holding History

Man Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-35,000	Closed	-$132K	–	2139
2023 Q4	$132K	Buy	+35,000	New	+$120K	﹤0.01%	1960
2023 Q1	–	Hold	0	–	–	–	1974
2021 Q3	–	Sell	-13,100	Closed	-$90K	–	1929
2021 Q2	$90K	Buy	+13,100	New	+$104K	﹤0.01%	1867

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Man Group's CRMD Position: Q1 2024 in Review

Man Group sold out of CorMedix (CRMD) in Q1 2024, closing a stake of 35,000 shares — an estimated $132K sold.

Man Group first reported a position in CRMD in Q2 2021 and held it in 2 quarters. The position peaked at $132K in Q4 2023. 91 funds tracked by Wall St. Rank hold CRMD as of Q1 2024.

Man Group reported no remaining CorMedix position as of Q1 2024 after selling out during the quarter.
Man Group sold 35,000 CorMedix shares in Q1 2024, an estimated $132K.
Man Group first reported a position in CorMedix in Q2 2021 and held it in 2 quarters.
Man Group's CorMedix position peaked at $132K in Q4 2023.
91 funds tracked by Wall St. Rank held CorMedix as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.